Dope Entrepreneurs
  • Research
  • News
  • Articles
  • Reviews
No Result
View All Result
  • Research
  • News
  • Articles
  • Reviews
No Result
View All Result
Dope Entrepreneurs
No Result
View All Result
Home Research

Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation

Could standardized microbiome therapies offer promising alternatives to fecal microbiota transplantation?

hplictawa@gmail.com' by Editorial Team
May 24, 2022
in Research
0
Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation
2.8k
SHARES
6.3k
VIEWS
Share on FacebookShare on TwitterShare On Whatsapp

Medically reviewed by Onikepe Adegbola, MD, PhD 

Standardized Microbiome Therapies In Recurrent C. difficile: Promising Alternatives To Fecal Microbiota Transplantation

A recent paper has highlighted the rapid scientific advancements happening in microbiome therapies for recurrent Clostridiodes difficile. This paper emphasizes that several alternatives to fecal microbial transplantation are underway, leading to the development of oral microbiome-based pharmaceutical products (Table 1). This advancement will certainly change the landscape of microbiome therapies, particularly in recurrent Clostridiodes difficile. This paper is titled “Microbiome therapy for recurrent Clostridioides difficile.” This 2022 paper has been published in The Lancet Microbe.

ADVERTISEMENT
Table 1. Emerging Standardized Microbiome Therapies for Recurrent Clostridiodes difficile
Innovating Company Molecule Therapy Type Development Stage Efficacy Results (Prevention of Clostridiodes difficile recurrence)
Seres Therapeutics SER-109 Donor stool-based oral capsules Phase 3 trial results announced. Demonstrated higher prevention of recurrence vs placebo in phase 3 trial (88% vs 60%, respectively)
Rebiotix RBX2660 Donor stool-based enema suspension Phase 3 trial results announced  Demonstrated higher prevention of recurrence vs placebo in phase 3 trial (70.4% vs 58.1%, respectively)
Finch Therapeutics CP101 Donor stool-based oral capsules Undergoing phase 3 trial Demonstrated higher prevention of recurrence vs placebo in phase 2 trial (74.5% vs 61.5%, respectively)
Destiny Pharma NTCD-M3 Cultured bacteria (non-stool-based) containing oral capsules  Completed phase 2 trials; phase 3 trial planned Demonstrated higher prevention of recurrence vs placebo in phase 2 trial (95% vs 70%, respectively) 
Vedanta Biosciences VE303 Cultured bacteria (non-stool-based) containing oral capsules Completed phase 2 trials; phase 3 trial planned Demonstrated higher prevention of recurrence vs placebo in phase 2 trial (86.2% vs 54.5%, respectively) 

As shown in Table 1, some of these therapies have completed phase 3 trials, while others are undergoing or yet to undergo phase 3 trials. The phase 3/phase 2 trial results for almost all of them appear very promising in terms of preventing the recurrence of Clostridiodes difficile. Most of these products are oral capsules, and only one is suspension for enemas.

What Does This Mean For Patients with Clostridiodes difficile?

Patients with Clostridiodes difficile frequently report recurrences. These patients may need a prolongation of antibiotic therapy and may need to be hospitalized. Such patients are currently being offered fecal microbial transplantation as a microbiome-based therapy.

But fecal microbial transplantation comes with many risks, such as the potential for the transmission of coronavirus or multidrug-resistant bacteria. Moreover, fecal microbial transplantation is a non-standard treatment as there can be differences in the donor stool.

In contrast, oral microbiome-based therapies are standardized, more convenient, and do not have risks of transmission of disease-causing viruses or bacteria. Thus, they can be considered a better therapy than fecal microbial transplantation.

What are the Key Takeaways From This Paper?

Though none of the newer microbiome-based products for preventing the recurrence of Clostridiodes difficile have yet been licensed, most of them are in advanced stages of development. It can be hoped that at least one of them may be licensed shortly by the regulators. Therefore, a new therapy for preventing the recurrence of Clostridiodes difficile may see the light of the day soon.

Reference:

Gilbert J. A. (2022). Microbiome therapy for recurrent Clostridioides difficile. The Lancet. Microbe, 3(5), e334. https://doi.org/10.1016/S2666-5247(22)00096-9

Tags: fecal microbiota transplantationsgutmicrobiome
hplictawa@gmail.com'

Editorial Team

Related Posts

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression
Research

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression

January 10, 2023
Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols
Research

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

January 10, 2023
FODMAP-Lowering Diet for IBS Patients
Research

FODMAP-Lowering Diet for IBS Patients

December 8, 2022
Next Post
IBD Patients Report Relatively Greater Fatigue; Anxiety & Steroid Use Possible Links

IBD Patients Report Relatively Greater Fatigue; Anxiety & Steroid Use Possible Links

Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome

Thailand Study Recommends Low FODMAP Diet For Patients Suffering From Gastric Reflux And Irritable Bowel Syndrome

Dutch Study Links Diet Quality With IBD And IBS Symptoms

Dutch Study Links Diet Quality With IBD And IBS Symptoms

Follow Us

  • 9.9k Followers

Recommended

Study Confirms a Direct Relationship of Gut Microbiota with the Brain

Study Confirms A Direct Relationship Of Gut Microbiota With The Brain

10 months ago
Brief Comparison of Effective IBS Treatments

Brief Comparison of Effective IBS Treatments

10 months ago
Gut Virome Can Treat Intestinal And Immunological Diseases

Gut Virome Can Treat Intestinal And Immunological Diseases

10 months ago
Dietary Choices Are Influenced By Gut Microbiota

Dietary Choices Are Influenced By Gut Microbiota

10 months ago

Categories

  • Articles
  • General
  • News
  • Research
  • Reviews

Topics

acid reflux antibiotics bloating capsaicin causes colonoscopy constipation Crohn's Disease deficiency diabetes diarrhea Digestive enzymes diverticulitis fatigue FODMAP gluten-free gut gut bacteria gut health gut microbiome gut microbiota health healthy diet IBD IBS IBS-C IBS diet inflammation inflammatory bowel disease irritable bowel syndrome lactobacillus low FODMAP diet microbiome microbiota peppermint oil probiotic probiotics quality of life research SIBO sucrose intolerance supplement tea therapy treatment
No Result
View All Result
https://casadesante.com https://casadesante.com https://casadesante.com

Highlights

Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

A Systematic Review of the Linkage Between Irritable Bowel Syndrome and Macronutrients

Invitation To Colonoscopy Reduced Incidences Of Cancer But Not Death Through A Gold-Standard Trial

Symptoms, Causes, and Solutions to Vitamin B Deficiencies

A Meta-Analysis: The Diagnostic Yield Of Colonoscopy In IBS Patients For Organic Diseases

Trending

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression
Research

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression

by Ivy Totanes
January 10, 2023
0

A recently published scientific report from Basel, Switzerland, has demonstrated that probiotics can supplement antidepressant treatment. The...

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

January 10, 2023
FODMAP-Lowering Diet for IBS Patients

FODMAP-Lowering Diet for IBS Patients

December 8, 2022
Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

October 25, 2022
Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

October 18, 2022
Dope Entrepreneurs

Dope Entrepreneurs is the hub for all dope gut health related content. We are a groundbreaking news publication dedicated to gut health. We cover gut health research, entrepreneurship, startups and the latest trends in gut health. We serve a growing segment of patients, entrepreneurs and investors who want to learn more about gut health, the disruption and market potential in this field, and how they can benefit from the latest advances in gut health. Dope entrepreneurs is led by Onikepe Adegbola, MD PhD DipIBLM, physician, scientist, and gut health entrepreneur.

Categories

  • Research
  • News
  • Articles
  • Reviews
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms And Conditions


© 2022 Dope Entrepreneurs

No Result
View All Result
  • Research
  • News
  • Articles
  • Reviews

© 2022 Dope Entrepreneurs

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist